Adriamycin, bleomycin, vinblastine and DTIC in advanced diffuse lymphocytic poorly differentiated lymphoma

E. Grigoletto, U. Tirelli, S. Tumolo, E. Galligioni, A. Veronesi, M. G. Trovò, G. Franchin, A. De Paoli, R. Volpe, A. Carbone

Research output: Contribution to journalArticle

Abstract

From January 1975 to December 1979, 14 consecutive patients with advanced (stage III-IV) diffuse lymphocytic, poorly differentiated lymphoma (DLPD) were treated with adriamycin, bleomycin, vinblastine and DTIC (ABVD). Either maintenance combination chemotherapy with CVP or radiotherapy over bulky disease was added in the cases with complete response (CR). Fifty per cent of the patients achieved CR and 80% achieved objective responses. Among CRs, 100% were alive at 2 years, 70% of them without evidence of disease. Overall, 75% of the patients were alive at 2 years, 30% without evidence of disease. Toxicity was acceptable and no drug-related deaths occurred. ABVD is not the ideal combination for DLPD, but it should be taken into consideration in patients with advanced DLPD in which first line combination chemotherapy regimens are not successful.

Original languageEnglish
Pages (from-to)477-481
Number of pages5
JournalTumori
Volume67
Issue number5
Publication statusPublished - 1981

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Adriamycin, bleomycin, vinblastine and DTIC in advanced diffuse lymphocytic poorly differentiated lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Grigoletto, E., Tirelli, U., Tumolo, S., Galligioni, E., Veronesi, A., Trovò, M. G., Franchin, G., De Paoli, A., Volpe, R., & Carbone, A. (1981). Adriamycin, bleomycin, vinblastine and DTIC in advanced diffuse lymphocytic poorly differentiated lymphoma. Tumori, 67(5), 477-481.